Insights into Doublet Therapy and Clinical Trial Takeaways for Metastatic Prostate Cancer Treatment : Episode 1
Therapeutic Combination Therapies for Metastatic Prostate Cancer
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic prostate cancer patients, with treatment selection influenced by factors such as disease volume and risk level.
The above content is prompted by the following:
- Discuss some therapeutic combinations for metastatic prostate cancer.
- What is the general rationale for using combination therapy (eg, androgen receptor–targeted agent and/or an androgen deprivation therapy with docetaxel)?
- How do disease volume and level of disease risk affect selection of therapy?
Recent Videos
Related Content
